Kolosis BIO and MTF Biologics Forge Strategic Partnership to Enter Surgical Incision Market

Kolosis BIO (Kolosis), a leading provider of biologics solutions, and MTF Biologics, a global tissue processor and nonprofit organization, are excited to announce their partnership in the surgical incision market.
Kolosis BIO and MTF Biologics Extend Exclusive Agreement

Kolosis BIO (Kolosis), a leading provider of orthobiologics solutions, and MTF Biologics, a global tissue processor and nonprofit organization, are proud to announce the extension of their successful partnership.
Kolosis BIO Announces Strong 2022 Results

Kolosis BIO, LLC (Kolosis), a pure-play biologics company and an exclusive bone graft partner to MTF Biologics, announced today its 2022 results and 2023 expectations.
Kolosis BIO Announces the Appointment of Charles Crockett as Area Vice President, East

Kolosis BIO, a privately-held pure-play orthobiologics company, announced today the appointment of Charles Crockett as Area Vice President of Sales, East.
Kolosis BIO Announces the Appointment of Michelle Soleimani-Mafi as Director of Operations

Kolosis BIO, a privately-held pure-play orthobiologics company, announced today the appointment of Michelle Soleimani-Mafi as its Director of Operations.
Kolosis BIO Announces 2021 Results

Kolosis BIO, LLC (Kolosis), a pure-play orthobiologics company and an exclusive partner to MTF Biologics, announced today its 2021 results and 2022 expectations.
Kolosis BIO Announces Relocation of its Headquarters to Historic Salt Lake Building

Salt Lake City, Utah, – Kolosis BIO, a privately-held pure-play orthobiologics company, announced today the relocation of its global headquarters to the historic Seed Building in downtown Salt Lake City.
Kolosis BIO to Exhibit at the 2022 Montana Orthopedic Society Meeting

Kolosis BIO, a privately-held pure-play orthobiologics company, announces its support of the 2022 Montana Orthopedic Society meeting, January 14-16 at the Yellowstone Conference Center in Big Sky, Montana.
Kolosis BIO Announces Release of Scientific White Paper

Salt Lake City, Utah – Kolosis BIO, a privately-held pure-play orthobiologics company, announced today the completion and release of a scientific white paper studying the effects of terminal sterilization on allograft tissues.
Kolosis BIO to Exhibit at the 2021 Society of Military Orthopedic Surgeons

Salt Lake City, Utah. – Kolosis BIO, a privately-held pure-play orthobiologics company, announces its support of the 2021 Society of Military Orthopedic Surgeons, December 14-17 at the Resort at Squaw Creek in Olympic Valley, California.